RE: Article Published Yesterday Mentions Hvivo10 Apr 2026 12:45
"What the Article is About
The article is a transcript of an investor presentation given on April 9, 2026, by Frederick Pierce, the CEO of Decoy Therapeutics (DCOY).
Decoy Therapeutics is a biotech company developing a new class of antiviral drugs called "D-MAVs" (Designable Multi-Antivirals). Instead of making one drug for one virus, they are using AI to design single nasal spray/inhaler drugs that can protect against and treat multiple viruses at once—such as their lead programs targeting a pan-coronavirus (funded by the Gates Foundation) and a triple-threat drug covering Flu, RSV, and COVID.
How hVIVO is Involved
During the presentation, the CEO explicitly named hVIVO when discussing how they plan to test these new drugs in humans.
He stated:
"And how we plan to clinically develop these programs... we are working toward a model with a company called hVIVO, which takes about a year from the start of your IND filing until you get your final study reports."
He goes on to describe exactly how they will use hVIVO's quarantine clinic for a Human Challenge Study. For their prophylactic (preventative) trial, they plan to put healthy volunteers into hVIVO's "hospital ward," give them the Decoy Therapeutics drug, and then deliberately expose them to SARS-CoV-2 (COVID) to prove the drug stops them from getting sick.
Does it Mean More Deals for hVIVO?
Yes, it strongly implies new, upcoming contracts for hVIVO. While they haven't announced a formally signed, multi-million-pound contract via an RNS yet, Decoy's CEO publicly stating to investors that they are "working toward a model" with hVIVO means hVIVO is their chosen partner for their clinical pathway.
Decoy outlined their timeline, stating they plan to bring their first pan-coronavirus program into the clinic in the first half of 2027, followed by their triple-virus drug in 2028. Because clinical trials take significant advance planning, hVIVO and Decoy are likely actively negotiating the contracts right now to lock in bed space at hVIVO's clinics for those 2027 trials.
For hVIVO investors, this is highly positive news. It shows that hVIVO remains the absolute "go-to" global gold standard for biotech companies needing to run respiratory human challenge trials, securing a pipeline of future revenues well into 2027 and 2028."
Sign In
Follow the stocks
